Investigating how mutations in specific RNA regions affect cancer's ability to evade the immune system

Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion

NIH-funded research Beth Israel Deaconess Medical Center · NIH-11015036

This study is looking at how changes in a specific part of RNA might help cancer cells hide from the immune system, which could lead to new ways to improve cancer treatments and make them work better for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBeth Israel Deaconess Medical Center NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11015036 on NIH RePORTER

What this research studies

This research focuses on understanding how mutations in the 3' untranslated regions (3'UTRs) of RNA can influence cancer cells' ability to escape detection by the immune system. By analyzing these mutations across various types of cancer, the study aims to uncover their role in tumor immune evasion and response to immunotherapy. The researchers will use advanced techniques, including spatial transcriptomics and bioinformatics, to identify and characterize these mutations, potentially leading to new biomarkers and therapeutic targets for cancer treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research include patients with various types of cancer who are undergoing or considering immunotherapy.

Not a fit: Patients with early-stage cancers that do not involve immune evasion mechanisms may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved cancer treatments by identifying new targets for immunotherapy and better patient stratification.

How similar studies have performed: Previous research has shown promise in targeting RNA mutations for cancer treatment, indicating that this approach may yield significant insights.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.